Bai S, Pei J, Chen K, Zhao Y, Cao H, Tian L, Ma Y and Dong H.
SLAS Discovery, 2020
Summary:
The assessment of drug proarrythmic potential has been widely assessed on human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-derived CMs). In this study, the risk of proarrythmic compounds from the Comprehensive In Vitro Proarrythmia Assay (CiPA) list could be correctly predicted in hiPSC-derived ventricular CM's paced at physiological beating rates. Recording of these responses was performed on an Axion multiwell multielectrode array (MEA) system.
